Palisade Bio, Inc.
PALI Healthcare Biotechnology
Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00. In the quarter to June 2026, revenue grew 19,900.0%, EPS grew 91.4% and free cash flow fell 318.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow PALI
Palisade Bio, Inc. (PALI) Piotroski F-score
Palisade Bio, Inc.'s Piotroski F-score for fiscal 2023 cannot be worked out: no comparable prior fiscal year (a missing year or a changed year end).
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2020 | 3 | 2.00 |
| FY2019 | 1 | (3.00) |
| FY2018 | 4 | (2.00) |
| FY2017 | 6 | 1.00 |
| FY2016 | 5 | — |
How fiscal 2023’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | — | — | n/a | — |
| Positive operating cash flow | (11.13m) | — | Fail | 0 |
| Rising return on assets | — | — | n/a | — |
| Cash flow above net income | 1.18m | — | Pass | 1 |
| Falling long-term leverage | — | — | n/a | — |
| Rising current ratio | 5.15 | — | n/a | — |
| No new shares issued | 456,000 | — | n/a | — |
| Rising gross margin | 100.00% | — | n/a | — |
| Rising asset turnover | — | — | n/a | — |
| Piotroski F-score | n/a — no comparable prior fiscal year (a missing year or a changed year end) | — | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| IPSC Century Therapeutics, Inc. compare | 4 |
| EYPT EyePoint, Inc. compare | 3 |
| OCGN Ocugen, Inc. compare | 2 |
| ABEO Abeona Therapeutics Inc. compare | — |
| PRLD Prelude Therapeutics Incorporated compare | — |
| NAUT Nautilus Biotechnology, Inc. compare | — |
| XFOR X4 Pharmaceuticals, Inc. compare | — |
| CABA Cabaletta Bio, Inc. compare | — |
| PALI Palisade Bio, Inc. | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover